Related Experiment Video
Updated: Jul 16, 2026
06:57
Chromogenic In Situ Hybridization as a Tool for HPV-Related Head and Neck Cancer Diagnosis
Published on: June 14, 2019
High-risk HPV type-specific clearance rates in cervical screening
N W J Bulkmans1, J Berkhof, S Bulk
1Department of Pathology, VU University Medical Center, Amsterdam, The Netherlands.
British Journal of Cancer
|March 8, 2007
Summary
High-risk human papillomavirus (hrHPV) clearance varies by type and cytology. HPV16 persistence in hrHPV-positive women with normal or borderline/mild dyskaryosis (BMD) smears is linked to increased cervical cancer risk, supporting targeted surveillance.
Area of Science:
- Gynecology
- Oncology
- Virology
Background:
- Cervical cancer screening relies on detecting high-risk human papillomavirus (hrHPV) types.
- Understanding hrHPV clearance rates is crucial for optimizing screening protocols and patient management.
- Cervical cytology results, including normal and borderline/mild dyskaryosis (BMD), influence hrHPV natural clearance.
Purpose of the Study:
- To evaluate the type-specific clearance rates of 14 hrHPV types in women with normal cytology and BMD.
- To determine the association between hrHPV persistence, particularly HPV16, and the risk of cervical intraepithelial neoplasia grade 3 (CIN3).
- To inform cervical screening program strategies based on hrHPV genotyping and clearance dynamics.
Main Methods:
- Analysis of a population-based cervical screening cohort of 44,102 women.
- Assessment of 6-month and 18-month hrHPV type-specific clearance rates in hrHPV-positive women.
- Comparison of clearance rates between women with normal cytology and those with BMD smears.
Main Results:
- 6-month hrHPV clearance rates were 43% (normal cytology) and 29% (BMD); 18-month rates were 65% (normal) and 41% (BMD).
- HPV16 and HPV31 showed significantly reduced 18-month clearance rates in normal cytology, while HPV16 clearance was markedly reduced in BMD.
- HPV16 persistence was associated with a significantly increased detection rate of >=CIN3 in both normal (P<0.0001) and BMD (P=0.005) groups.
Conclusions:
- Type-specific hrHPV clearance rates vary, highlighting the potential utility of hrHPV genotyping in cervical screening.
- Close surveillance is recommended for women with HPV16, while management for HPV18, HPV31, and HPV33 requires further investigation.
- A conservative management approach with extended waiting periods is advisable for other hrHPV-positive women due to higher clearance rates at 18 months and low risk of >=CIN3.